OpenBit ResearchOpenBit
中文

What's driving Acadia Pharmaceuticals (ACAD)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Can remlifanserin advance in Alzheimer’s disease psychosis?

Why it matters now

Revisions to the probability and magnitude of remlifanserin’s clinical-development success can affect ACAD’s valuation through the program’s potential product value; the program also affects prospective revenue.

Next checkpoint

ACAD earnings (expected 2026-11-04)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to ACAD, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Phase 3 evidence fails to reproduce the 60 mg efficacy signal or identifies a material safety, motor-symptom, or cognition problem.

Research drivers

  • Can remlifanserin advance in Alzheimer’s disease psychosis?

    Bullish · Cooling · Updated

    The reported results support continued evaluation of 60 mg remlifanserin, but the mixed endpoint strength leaves clinical efficacy subject to confirmation in Phase 3.

  • Trofinetide Patent Protection

    Bullish · Cooling · Updated

    The allowed application supports an emerging view that trofinetide U.S. patent protection may extend to March 2041, but the economic effect remains conditional on patent issuance and enforceable scope.

  • Can remlifanserin advance in Lewy body dementia psychosis?

    Neutral · Cooling · Updated

    Remlifanserin is being evaluated in a separate Phase 2 trial for Lewy body dementia psychosis, with efficacy and development prospects not yet established by the supplied evidence.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • Acadia Pharmaceuticals announced that the USPTO issued a notice of allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.”

    Relayed by: Benzinga · Event date on record:

  • There was no signal of QT prolongation versus placebo.

    Relayed by: Benzinga · Event date on record:

  • Acadia announced Phase 3-enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis.

    Relayed by: Benzinga · Event date on record:

  • The difference between 60 mg remlifanserin and placebo increased through the six-week treatment period on both efficacy measures.

    Relayed by: Benzinga · Event date on record:

  • Across both doses, remlifanserin had adverse-event, serious-adverse-event, and adverse-event discontinuation rates similar to placebo.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.